UNSPSC 51373101: Diethylthiambutene

This classification denotes an opioid receptor agonist with the molecular formula C16H21NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z91X9052O, chemically known as 3-diethylamino-1,1-dithienylbut-1-ene but generally known as diethylthiambutene, which bears US NIH Compound Identifier 6833. European Medicines Agency schedules Diethylthiambutene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07113MIG. The term DIETHYLTHIAMBUTENE is an International Non-Proprietary Name.

UNSPSC 51373101 Diethylthiambutene is a Commodity code that nominally identifies a specific opioid pharmaceutical compound, but recent state and local procurement activity under this code does not reflect purchases of diethylthiambutene itself. Instead, issuing bodies are soliciting naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. The mismatch between the code's nominal scope and actual procurement activity suggests either a classification error in how opportunities are tagged or a shift in how the code is being applied operationally. State and local buyers using this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work being solicited ranges from clinical and community health supplies (naloxone kits and drug deactivation systems for opioid response) to broader pharmaceutical procurement through established wholesaler distribution channels.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. MMCAP's procurement emphasizes wholesaler-direct relationships with three authorized distributors, cGMP and Drug Supply Chain Security Act certification, and price competitiveness weighted at 75 percent of evaluation scoring.